628 related articles for article (PubMed ID: 14627905)
1. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation.
Cherikh WS; Kauffman HM; McBride MA; Maghirang J; Swinnen LJ; Hanto DW
Transplantation; 2003 Nov; 76(9):1289-93. PubMed ID: 14627905
[TBL] [Abstract][Full Text] [Related]
2. Use of antilymphocyte induction therapy in liver transplantation.
Wall WJ
Liver Transpl Surg; 1999 Jul; 5(4 Suppl 1):S64-70. PubMed ID: 10431019
[TBL] [Abstract][Full Text] [Related]
3. Lymphoproliferative disorders and de novo malignancies in intestinal and multivisceral recipients: improved outcomes with new outlooks.
Abu-Elmagd KM; Mazariegos G; Costa G; Soltys K; Bond G; Sindhi R; Green M; Jaffe R; Wu T; Koritsky D; Matarese L; Schuster B; Martin L; Dvorchik I; Nalesnik MA
Transplantation; 2009 Oct; 88(7):926-34. PubMed ID: 19935465
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up of kidney transplant patients with posttransplant lymphoproliferative disorder: duration of posttransplant lymphoproliferative disorder-induced operational graft tolerance, interleukin-18 course, and results of retransplantation.
Birkeland SA; Hamilton-Dutoit S; Bendtzen K
Transplantation; 2003 Jul; 76(1):153-8. PubMed ID: 12865802
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-2 receptor antibody does not reduce rejection risk in low immunological risk or tacrolimus-treated intermediate immunological risk renal transplant recipients.
Lim WH; Chadban SJ; Campbell S; Dent H; Russ GR; McDonald SP
Nephrology (Carlton); 2010 Apr; 15(3):368-76. PubMed ID: 20470309
[TBL] [Abstract][Full Text] [Related]
6. Lymphoproliferative disorders after adult kidney transplant: epidemiology and comparison of registry report with claims-based diagnoses.
Kasiske BL; Kukla A; Thomas D; Wood Ives J; Snyder JJ; Qiu Y; Peng Y; Dharnidharka VR; Israni AK
Am J Kidney Dis; 2011 Dec; 58(6):971-80. PubMed ID: 21930332
[TBL] [Abstract][Full Text] [Related]
7. Prevention of acute rejection with antithymocyte globulin (Thymoglobuline): its potential to reduce corticosteroids.
Cantarovich D
J Nephrol; 2004; 17 Suppl 8():S40-6. PubMed ID: 15599885
[TBL] [Abstract][Full Text] [Related]
8. A randomized, placebo-controlled trial with anti-interleukin-2 receptor antibody for immunosuppressive induction therapy after liver transplantation.
Langrehr JM; Glanemann M; Guckelberger O; Klupp J; Neumann U; Machens C; Lohmann R; Knoop M; Lobeck H; Schlag H; Keck H; Settmacher U; Bechstein WO; Neuhaus PJ
Clin Transplant; 1998 Aug; 12(4):303-12. PubMed ID: 9686324
[TBL] [Abstract][Full Text] [Related]
9. Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation.
Opelz G; Döhler B;
Transplantation; 2009 Mar; 87(6):795-802. PubMed ID: 19300179
[TBL] [Abstract][Full Text] [Related]
10. Risk for post-transplant lymphoproliferative disorder after polyclonal antibody induction in kidney transplantation.
Dharnidharka VR; Stevens G
Pediatr Transplant; 2005 Oct; 9(5):622-6. PubMed ID: 16176420
[TBL] [Abstract][Full Text] [Related]
11. 20-year follow-up results of a randomized controlled trial comparing antilymphocyte globulin induction to no induction in renal transplant patients.
Cantarovich M; Durrbach A; Hiesse C; Ladouceur M; Benoit G; Charpentier B
Transplantation; 2008 Dec; 86(12):1732-7. PubMed ID: 19104413
[TBL] [Abstract][Full Text] [Related]
12. Cold ischemia is a major determinant of acute rejection and renal graft survival in the modern era of immunosuppression.
Mikhalski D; Wissing KM; Ghisdal L; Broeders N; Touly M; Hoang AD; Loi P; Mboti F; Donckier V; Vereerstraeten P; Abramowicz D
Transplantation; 2008 Apr; 85(7 Suppl):S3-9. PubMed ID: 18401260
[TBL] [Abstract][Full Text] [Related]
13. Acute rejection and late renal transplant failure: risk factors and prognosis.
Pallardó Mateu LM; Sancho Calabuig A; Capdevila Plaza L; Franco Esteve A
Nephrol Dial Transplant; 2004 Jun; 19 Suppl 3():iii38-42. PubMed ID: 15192134
[TBL] [Abstract][Full Text] [Related]
14. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients.
Younes BS; McDiarmid SV; Martin MG; Vargas JH; Goss JA; Busuttil RW; Ament ME
Transplantation; 2000 Jul; 70(1):94-9. PubMed ID: 10919581
[TBL] [Abstract][Full Text] [Related]
15. Daclizumab is associated with decreased rejection and improved patient survival in renal transplant recipients.
Morris JA; Hanson JE; Steffen BJ; Chu AH; Chi-Burris KS; Gotz VP; Gordon RD
Clin Transplant; 2005 Jun; 19(3):340-5. PubMed ID: 15877795
[TBL] [Abstract][Full Text] [Related]
16. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin.
Mai ML; Ahsan N; Wadei HM; Genco PV; Geiger XJ; Willingham DL; Taner CB; Hewitt WR; Grewal HP; Nguyen JH; Hughes CB; Gonwa TA
Transplantation; 2009 Jan; 87(2):227-32. PubMed ID: 19155977
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-2 receptor antibody reduces rejection rates and graft loss in live-donor kidney transplant recipients.
Lim WH; Chang SH; Chadban SJ; Campbell SB; Dent H; Russ GR; McDonald SP
Transplantation; 2009 Nov; 88(10):1208-13. PubMed ID: 19935375
[TBL] [Abstract][Full Text] [Related]
18. Increased risk for posttransplant lymphoproliferative disease in recipients of liver transplants with hepatitis C.
McLaughlin K; Wajstaub S; Marotta P; Adams P; Grant DR; Wall WJ; Jevnikar AM; Rizkalla KS
Liver Transpl; 2000 Sep; 6(5):570-4. PubMed ID: 10980055
[TBL] [Abstract][Full Text] [Related]
19. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients.
Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV
Transplantation; 2012 Jan; 93(1):73-81. PubMed ID: 22129761
[TBL] [Abstract][Full Text] [Related]
20. Daclizumab is associated with decreased rejection and no increased mortality in cardiac transplant patients receiving MMF, cyclosporine, and corticosteroids.
Kobashigawa J; David K; Morris J; Chu AH; Steffen BJ; Gotz VP; Gordon RD
Transplant Proc; 2005 Mar; 37(2):1333-9. PubMed ID: 15848713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
